Log In
Print
BCIQ
Print
Print this Print this
 

N9-GP, Pegylated recombinant human Factor IX (PEG-rFIX)

Also known as: formerly NN7999

  Manage Alerts
Collapse Summary General Information
Company Novo Nordisk A/S
DescriptionGlyco-pegylated derivative of recombinant human Factor IX
Molecular Target Factor IX
Mechanism of ActionFactor IX replacement
Therapeutic ModalityBiologic: Protein
Latest Stage of DevelopmentPhase III
Standard IndicationHemophilia
Indication DetailsTreat and prevent bleeding episodes in patients with hemophilia B; Treat hemophilia B
Regulatory Designation Switzerland - Orphan Drug (Treat hemophilia B)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today